Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998528 · ClinicalTrials.gov registry record · Phase 3
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 505
- Enrollment target
NCT02998528 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 505 participants.
The verdict
NCT02998528, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 505 participants
- Enrollment target
Study Summary
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoints.
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Gemcitabine
- BIOLOGICAL Nivolumab
- DRUG Vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2017-03-04 |
| Est. Completion | 2024-12-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998528
The ClinicalTrials.gov registry entry for NCT02998528 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 505 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT02998528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02998528 about?
NCT02998528 is a clinical study titled "A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)". The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoints.
What is the current status of trial NCT02998528?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 505 participants. The study started on 2017-03-04. Estimated completion is 2024-12-06.
What interventions are being tested in trial NCT02998528?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Nivolumab (BIOLOGICAL), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT02998528?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.